Table 3

Hazard ratio (95% CI) for the sulfonylurea monotherapy comparisons for mortality in the entire cohort and the subgroup with documented CAD

Hazard ratio (95% CI)P value
Entire cohort contrast
    Glyburide vs. glimepiride1.00 (0.89–1.14)0.952
    Glipizide vs. glyburide1.04 (0.94–1.15)0.430
    Glipizide vs. glimepiride1.05 (0.92–1.19)0.499
CAD subgroup contrast
    Glyburide vs. glimepiride1.36 (0.96–1.91)0.081
    Glipizide vs. glyburide1.03 (0.80–1.31)0.838
    Glipizide vs. glimepiride1.39 (0.99–1.96)0.059
  • Mortality model adjusted for baseline covariates: age, sex, race (Caucasian vs. non-Caucasian), Modification of Diet in Renal Disease estimated glomerular filtration rate, A1C, BMI, systolic blood pressure, diastolic blood pressure, HDL cholesterol, LDL cholesterol, triglycerides, smoking status, ACE or angiotensin receptor blocker therapy, aspirin therapy, clopidogrel therapy, cholesterol-lowering medication, new diabetes, CAD, congestive heart failure, and median household income.